Olema Pharmaceuticals, Inc. 8-K

What Happened
On May 26, 2026, Olema Pharmaceuticals, Inc. announced (via press release attached as Exhibit 99.1 to an 8‑K) that it entered a clinical trial collaboration and supply agreement with Bayer Consumer Care AG. Under the Agreement, Olema and Bayer will evaluate OP-3136 (Olema’s KAT6 inhibitor) in combination with Bayer’s androgen receptor inhibitor NUBEQA® (darolutamide) in a Phase 1b/2 study of approximately 36 patients with metastatic castration‑resistant prostate cancer (mCRPC). The trial is expected to initiate in the second half of 2026. Bayer will supply darolutamide; Olema will lead study conduct. All clinical data and inventions related to the combination will be jointly owned, and Olema retains full global commercial and marketing rights to OP-3136.

Key Details

• Date announced: May 26, 2026 (press release filed on Form 8‑K; Exhibit 99.1 furnished).
• Trial: Phase 1b/2, ~36 mCRPC patients; expected start in H2 2026.
• Roles: Bayer supplies darolutamide (NUBEQA®); Olema leads the trial conduct.
• IP & rights: Clinical data and inventions from the combo are jointly owned; Olema keeps full global commercial/marketing rights to OP-3136. This is OP-3136’s first clinical collaboration.

Why It Matters
This agreement creates a near‑term clinical catalyst for Olema (trial start planned H2 2026) and pairs its investigational KAT6 inhibitor with an approved prostate cancer therapy from a large pharmaceutical partner, which may accelerate combination data generation. Importantly for investors, Olema retains commercial rights to OP-3136 (preserving potential future upside) while sharing clinical data ownership with Bayer. The filing does not disclose financial terms. The press release information was furnished, not filed, and includes customary forward‑looking statements.